JPM 9.64ATD.TO 0.76MTD 11.7401CRWD -30.31AMD -22.52AVGO -60.825TVE.TO 0.37
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

25.71
+0.37 (1.46%)
as of Jun 4, 2026, 6:38:50 pm Market Open.
579 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 4, 2026, 12:00 am

This summary was created by AI, based on 31 opinions in the last 12 months.

Pfizer Inc (PFE) is facing significant challenges stemming from a patent cliff, leading to concerns about its drug pipeline and growth prospects in the coming years. Analysts emphasize the company's attractive dividend yield, which hovers around 6-7%, making it appealing for income-focused investors. However, many reviews suggest that the lack of earnings momentum and the need for new blockbuster drugs remain critical issues. Despite a robust pipeline and recent acquisitions, the absence of immediate catalysts for growth has left investors cautious. Overall, while Pfizer provides a decent dividend, its future performance hinges on successful drug development and navigating market sentiment around healthcare reforms.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
NVO
HOLD

Pfizer Inc(PFE)

Feb 06, 2020
Trades at 14-15x earnings. Great dividend, almost 4%. Always pressure to develop drugs in the pipeline. Will have difficulty going into an election. Should do well over the long run.
Photo of Paul Harris, CFAPaul Harris, CFAUnlock Rating
$38.26

Stock price when the opinion was issued

$25.68

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Jan 30, 2020
The only way they are growing is through massive cost cutting and acquisition. These stocks will all give you dividend growth and decent cash flow. One of their star pain killers is off patent.
Photo of Lorne SteinbergLorne SteinbergUnlock Rating
$37.07

Stock price when the opinion was issued

$25.68

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jan 29, 2020
It's performed by cutting costs, not by growth. The reason is that as they develop new drugs, they go off-patent and lose billions. It's a cost story, simply. You're spinning your wheels here.
Photo of Gordon ReidGordon ReidUnlock Rating
$37.58

Stock price when the opinion was issued

$25.68

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jan 17, 2020
He takes a contrarian view as the company reorganizes its business. They are making acquisitions including in the oncology and vaccine business. There are some big drugs coming out of the pipeline. They are becoming more focused on R&D and building out their pipeline. They have around 15 phase 3 drugs right now. Patent expiry is what you have to watch for with this name. (Analysts’ price target is $42.54)
Photo of Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$40.51

Stock price when the opinion was issued

$25.68

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Jan 17, 2020

He was concerned that GSK was getting more growth focused. They spun off their consumer products with Novartis, giving up their oncology department. Now they have a joint venture with Pfizer. Having it as a longterm asset is probably positive.

Photo of Paul MacDonaldPaul MacDonaldUnlock Rating
$40.51

Stock price when the opinion was issued

$25.68

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 10, 2020
(A Top Pick Feb 08/19, Down 4%) All the drug stocks look so cheap here. His model price is $50.43.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$39.49

Stock price when the opinion was issued

$25.68

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Dec 05, 2019
(A Top Pick Feb 08/19, Down 7%) All the drugs have been moving spectacularly. There is a lot of value. His model price is 48.79 or a 28% upside. If we have a fall, these stocks will do very well.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$38.03

Stock price when the opinion was issued

$25.68

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Nov 21, 2019
(A Top Pick Dec 06/18, Down 13%) Under pressure due to patent loss and divesting off-patent division. Dividend is 3.9% and looks secure. Political noise has hurt healthcare. This is an opportunity. Starting to launch potential blockbuster drugs.
Photo of Stan WongStan Wong
Owned
Unlock Rating
$37.74

Stock price when the opinion was issued

$25.68

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Nov 19, 2019
(A Top Pick Sep 09/19, Up 4%) He doesn't see upside in the drug space. He won't sell it, but won't add to it. This sector will be quiet as others rally. Hold.
Photo of Elliott FishmanElliott Fishman
Owned
Unlock Rating
$37.66

Stock price when the opinion was issued

$25.68

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Oct 24, 2019
Dropped off with the spinoff. Very good dividend. Undervalued here because of political pressure. That's an opportunity. Healthcare companies tend to do well when the economic cycle matures. Be patient. Value stocks are emerging from their underperformance. Yield is 4%. (Analysts’ price target is $41.77)
Photo of Stan WongStan Wong
Owned
Unlock Rating
N/A

Stock price when the opinion was issued

$25.68

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
WAIT

Pfizer Inc(PFE)

Oct 22, 2019
He liked this before, but has suffered a setback. The MFV is 37% higher than the present price. The earnings forecasts are rolling over, which worries him--it's a warning of bad things to come. He wouldn't buy this unless it fell to $30. Pays a 4% yield. Wait.
Photo of Ross HealyRoss Healy
No
Unlock Rating
$36.43

Stock price when the opinion was issued

$25.68

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Oct 17, 2019

Real topline struggles over the past decade. Blockbusters go off patent and have to be replaced. Like bailing a leaky boat. You can only cut costs to make money for so long. If he had to pick one, he'd pick Merck. Their pipeline is superior to peers, and well managed. But he wouldn't own the industry at this point in the cycle.

Photo of Gordon ReidGordon ReidUnlock Rating
$36.50

Stock price when the opinion was issued

$25.68

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 24, 2019
Weak in the healthcare space. It's currently at support level, and it is entering seasonal weakness in mid-October.
Photo of Brooke ThackrayBrooke ThackrayUnlock Rating
$36.02

Stock price when the opinion was issued

$25.68

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 16, 2019
He's bought and sold this at $43. They're Upjohn division is merging with Mylan and will spin it out. This will likely lead to the stock returning to the mid-$40's (Analysts’ price target is $42.75)
Photo of Bruce MurrayBruce Murray
No
Unlock Rating
$36.83

Stock price when the opinion was issued

$25.68

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 06, 2019
It has long term support levels. At a great spot, and it is consolidating well. Would take advantage of the pullback here. The risk is to go up not down.
Photo of Elliott FishmanElliott Fishman
No
Unlock Rating
$36.50

Stock price when the opinion was issued

$25.68

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
Showing 211 to 225 of 883 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

BHP -2.05$88.8
TA.TO -2.08$18
V 7.75$320.15
TOU.TO -0.12$65.42
NVO 1.79$43.79

Today's Top Picks

JPM 9.64$310.49
ATD.TO 0.76$80.79
MTD 11.74$1181.0601
CRWD -30.31$717.3
AMD -22.52$520

Popular Articles

Latest Sell Signals

PRL.TO 0.07$21.2
CNQ.TO -0.14$66.22
SHOP.TO 4.46$161.54
RIO -2.605$105.255
BB.TO 0.3$14.4

Most Recent Experts

Darren Sissons

Darren Sissons

Campbell Lee & Ross

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Bryn Talkington

Bryn Talkington

Requisite Capital Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica